TTT1 study
Research type
Research Study
Full title
Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin
IRAS ID
254431
Contact name
John Petrie
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
Eudract number
2018-004120-11
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 9 months, 31 days
Research summary
The study will ask whether adding dapagliflozin (a drug that increases the amount of sugar removed from your body) and semaglutide (a drug than increases insulin secretion) to standard insulin treatment can improve blood sugar control and improve blood pressure, body weight and quality of life in patients with type 1 diabetes. The study will be conducted in two centers (one in Buffalo, US and one in Glasgow, UK). Participants will be assigned to one of the three treatment arms and followed up for 1 year. One hundred and fourteen people with type 1 diabetes aged 18-65 years and with current HbA1c >8.0 % will be invited to take part.
57 participants (50%) will be recruited from each site.
During the first six months, those who agree will either continue on their usual insulin treatment or start semaglutide along with their usual insulin.
During the second six months, those who were taking semaglutide in the first six months will either continue to take it along with either active dapagliflozin medication or a matching inactive placebo. Both investigators and participants will be blinded to this allocation until the study has finished. The group taking usual insulin treatment in the first six months will continue as before, and all participants will have the same number of study visits and assessments.REC name
West of Scotland REC 1
REC reference
20/WS/0030
Date of REC Opinion
9 Mar 2020
REC opinion
Further Information Favourable Opinion